Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0TRKTX
ADC Name
A5/158-vc-MMAE
Synonyms
A5/158-Val-Cit-MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Soft tissue sarcoma [ICD11:2B5F]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
A5/158
  Antibody Info 
Antigen Name
C-type mannose receptor 2 (MRC2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 91.2
%
MG-63 cells
Osteosarcoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 91.20% (Day 32) Positive MRC2 expression (MRC2 +++/++)
Method Description
Vehicle (PBS) or 10 mg/kg of A5/158-vc-MMAE were administered into the lateral tail vein of mice twice a week for 2 weeks. Primary tumors were weighed at necropsy.
In Vivo Model MG-63-mChLuc2 CDX model
In Vitro Model Osteosarcoma MG-63 cells CVCL_0426
References
Ref 1 Endo180 (MRC2) Antibody-Drug Conjugate for the Treatment of Sarcoma. Mol Cancer Ther. 2023 Feb 1;22(2):240-253. doi: 10.1158/1535-7163.MCT-22-0312.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.